(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® (naloxone HCl) Nasal Spray ...
(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial ... Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use ...
(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial ... Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the ...
(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial ... Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the ...
(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial ... Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the ...
Barbara Bellesi Zito is a freelance writer from Staten Island, covering all things real estate and home improvement. When she's not watching house flipping shows or dreaming about buying a vacation ...
Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial ... who can use it to ...